Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Pharmaceutical Outsourcing Present and Future

The need for preclinical testing expertise is growing as molecular complexity increases.

Navigating the Preclinical CRO Outsourcing Process

A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.

A Closer Look at Affinity Ligands

Topic

Ranjit Deshmukh is Principal at BiologixCMC.

Videos

Ranjit Deshmukh, Principal, BiologixCMC, discusses how contract manufacturers can optimize their processes and plan for the future by optimizing facility design. 

Facility Design for Optimized Contract Manufacturing

Articles

Asahi Kasei acquires Aicuris, adding three antiviral assets targeting immunocompromised patients, with combined revenue projected at $500M by 2030.

Asahi Kasei's Aicuris Acquisition Targets Infectious Disease Therapies

Melanie Cerullo is chief quality officer at Kindeva.

Contract development and manufacturing organizations can assist the sponsor company in ensuring sterility assurance in alignment with the EU’s Annex 1 guidelines.

Is Your Annex 1 Strategy a Static Document or a Dynamic Defense?

SGD Pharma and Prince launch sterile Type I glass nasal vials for the US market, targeting complex chronic conditions like Alzheimer's and Parkinson's.

SGD Pharma Launches Sterile Nasal Vial Platform for US Market

The two companies have entered into a licensing agreement to commercialize biosimilars in Latin America.

SteinCares and Shilpa Biologicals Collaborate on Biosimilar Access for Latin America

The companies have extended a commercial supply partnership for the manufacture of Sohonos (palovarotene), which is a treatment for the ultra-rare disease, fibrodysplasia ossificans progressiva.

Quotient Sciences Extends Partnership with Ipsen for Manufacture of Ultra-Rare Disease Treatment

Lars Hahn is senior vice-president, Global Sales Organization, at Vetter.

Trust-based CDMO partnerships are becoming essential to accelerate injectable drug development, manage risk, and ensure resilient biopharma supply.

Navigating Biopharma Complexity: Why Long-Term Partnerships Matter 

Katie Edgar is chief business officer at KBI Biopharma.

Innovators are increasingly focused on whether outsourced partners can help them make better decisions earlier, before uncertainty becomes late-stage risk. 

How Innovation Is Reshaping Outsourced Development and Manufacturing 

Industry experts discuss the benefits of utilizing contract development and contract research organizations in drug discovery and development. 

Outsourcing Formulation Activities May Advance Drug Development

Andrew Mitchell is associate vice president of Business Development at BioVectra.

PharmTech spoke with Andrew Mitchell, associate vice president of Business Development at BioVectra, about which 2025 trends will continue to impact the pharma industry and how CDMOs can offer solutions.